Recent Updates
Recently added Catalysts
EBS Positive Sentiment Score: 70/100

Emergent BioSolutions Announces Amendment to its Existing Credit Facility

Key Takeaway: Emergent BioSolutions Inc. announced a significant amendment to its existing credit facility, providing the company with an extended runway to stabilize its financial position. CEO Joe Papa emphasized the constructive collaboration with their banking partners, indicating a positive step forward for the company's business plan. Emergent will also report its Q1 2024 financial results and provide guidance for the upcoming quarters, showcasing an active engagement with its financial stakeholders.

Market Sentiment Analysis

POSITIVE FACTORS

  • The amendment provides Emergent BioSolutions with more time to stabilize its financial position.
  • The company's management is working constructively with its bank group.
  • The upcoming financial results announcement suggests proactive communication with stakeholders.

Full Press Release Details

GAITHERSBURG, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that it has entered into a “Consent, Waiver and Seventh Amendment” to its existing credit facility.
“In light of this amendment, Emergent now has an extended runway to execute on our go-forward business plan to stabilize our financial position,” stated Joe Papa, president and CEO of Emergent. “Our bank group continues to work with our management team in a constructive fashion, evidenced by this positive development.”
On May 1, 2024, Emergent will report its first quarter 2024 financial results via conference call, as well highlight key business updates, Q1 2024 financial review, and FY 2024 and Q2 2024 guidance.
About Emergent BioSolutions
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “intend,” “may,” “plan,” “position,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statements will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statement speaks only as of the date of this press release and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause our actual results to differ materially from those indicated by any forward-looking statements. Readers should consider this cautionary statement, as well as the risk factors and other disclosures included in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.
Executive Vice President, CFO
Vice President, Communications

Frequently Asked Questions

What has Emergent BioSolutions recently announced?

Emergent BioSolutions has announced a 'Consent, Waiver and Seventh Amendment' to its credit facility.

How will the amendment affect Emergent's business?

The amendment provides Emergent with an extended runway to stabilize its financial position.

When will Emergent report its Q1 2024 financial results?

Emergent will report its Q1 2024 financial results on May 1, 2024.

Who is Emergent's CEO?

Joe Papa is the president and CEO of Emergent BioSolutions Inc.

What is included in the safe harbor statement?

The safe harbor statement cautions that forward-looking statements could differ from actual results.

Last updated: Apr 30, 2024